ARTICLE | Company News
Bavarian Nordic infectious, cancer news
October 11, 2010 7:00 AM UTC
The cancer vaccines division will focus on development of the prostate cancer vaccine ProstVac, acquisitions and developing new targets. A Phase III trial for ProstVac is expected to start next year. The infectious diseases division will focus on delivering the Imvamune smallpox vaccine to the HHS's Strategic National Stockpile, securing additional Imvamune orders and developing new late-stage vaccines for infectious diseases. Imvamune, which received delivery clearance in March, has completed Phase II testing (see BioCentury, March 22). ...